|Videos|June 28, 2023

Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

Author(s)Binod Dhakal, MD, MS, Joseph R. Mikhael, MD, Cindy Varga, MD

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Episodes in this series

$EP. 1 Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)$

EP. 1 Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

EP. 2 Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

EP. 2 Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

EP. 3 MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

EP. 3 MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

EP. 4 FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

EP. 4 FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

EP. 5 Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

EP. 5 Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

EP. 6 Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

EP. 6 Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

EP. 7 Best Practices for Transition of Care in Patients with MM on Teclistamab

EP. 7 Best Practices for Transition of Care in Patients with MM on Teclistamab

EP. 8 Managing Infections and Other Toxicities Associated with Bispecifics in MM

EP. 8 Managing Infections and Other Toxicities Associated with Bispecifics in MM

EP. 9 Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

EP. 9 Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

EP. 10 Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

EP. 10 Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

EP. 11 Future Perspectives on the Role of Bispecifics in MM

EP. 11 Future Perspectives on the Role of Bispecifics in MM

EP. 12 Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

EP. 12 Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

$EP. 13 Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma$

EP. 13 Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

EP. 14 Treatment Recommendations for Relapsed Multiple Myeloma

EP. 14 Treatment Recommendations for Relapsed Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Treatment Strategies in Multiple Myeloma are Changing: © stock_acc - stock.adobe.com

September 12th, 2026

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Trending on CancerNetwork

CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer